INTRODUCTION.On January 7,2025,at 9:05 AM BJT,a MS6.8 earthquake(CENC epicenter:28.50°N,87.45°E)struck Dingri County,Xizang Province(hereinafter referred to as the Dingri mainshock).The inferred moment magni...INTRODUCTION.On January 7,2025,at 9:05 AM BJT,a MS6.8 earthquake(CENC epicenter:28.50°N,87.45°E)struck Dingri County,Xizang Province(hereinafter referred to as the Dingri mainshock).The inferred moment magnitude,based on regional/teleseismic waveform inversion and back-projection,is approximately MW7.1.Focal mechanism solutions,aftershock distribution,and field surveys indicate that the Dingri mainshock was a normal-faulting event,with a nearly north-south strike and a westward-dipping fault plane.展开更多
BACKGROUND Treating diabetes in dialysis patients remains a challenge,with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.CASE SUMMARY This report describes an 83-year-old female pat...BACKGROUND Treating diabetes in dialysis patients remains a challenge,with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.CASE SUMMARY This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes(T2DM)who had struggled to control her blood sugar for more than a year.She had a history of high blood pressure for 30 years,had undergone continuous ambulatory peritoneal dialysis for more than two years,was 163 cm tall,weighed 77 kg,and had a body mass index of 28.98 kg/m2.Despite intensive insulin therapy at a daily dose of 150 units,adding Dorzagliatin at a dosage of 75 mg orally twice daily led to immediate blood sugar improvement and a gradual reduction in insulin dosage.After one month of follow-up,the fasting plasma glucose was 6-8 mmol/L,and the 2-hour postprandial glucose was 8-12 mmol/L.CONCLUSION To our knowledge,this report is the first to use Dorzagliatin to treat type 2 diabetes peritoneal dialysis patients with challenging glucose control.Dorzagliatin,a novel glucokinase activator primarily metabolized by the liver,exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease.It has a high plasma protein binding rate and may not be cleared by peritoneal dialysis,potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.展开更多
基金supported by the“CUG Scholar”Scientific Research Funds at China University of Geosciences(Wuhan)(No.2021230)supported by the National Natural Science Foundation of China(Nos.41922025,42204062)。
文摘INTRODUCTION.On January 7,2025,at 9:05 AM BJT,a MS6.8 earthquake(CENC epicenter:28.50°N,87.45°E)struck Dingri County,Xizang Province(hereinafter referred to as the Dingri mainshock).The inferred moment magnitude,based on regional/teleseismic waveform inversion and back-projection,is approximately MW7.1.Focal mechanism solutions,aftershock distribution,and field surveys indicate that the Dingri mainshock was a normal-faulting event,with a nearly north-south strike and a westward-dipping fault plane.
文摘BACKGROUND Treating diabetes in dialysis patients remains a challenge,with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.CASE SUMMARY This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes(T2DM)who had struggled to control her blood sugar for more than a year.She had a history of high blood pressure for 30 years,had undergone continuous ambulatory peritoneal dialysis for more than two years,was 163 cm tall,weighed 77 kg,and had a body mass index of 28.98 kg/m2.Despite intensive insulin therapy at a daily dose of 150 units,adding Dorzagliatin at a dosage of 75 mg orally twice daily led to immediate blood sugar improvement and a gradual reduction in insulin dosage.After one month of follow-up,the fasting plasma glucose was 6-8 mmol/L,and the 2-hour postprandial glucose was 8-12 mmol/L.CONCLUSION To our knowledge,this report is the first to use Dorzagliatin to treat type 2 diabetes peritoneal dialysis patients with challenging glucose control.Dorzagliatin,a novel glucokinase activator primarily metabolized by the liver,exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease.It has a high plasma protein binding rate and may not be cleared by peritoneal dialysis,potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.
